Alkermes plc is soliciting proxies for its 2026 annual meeting on May 20 in Dublin, where shareholders will elect directors, cast advisory votes on executive pay and auditor ratification, and consider approval of the amended 2018 stock plan and renewed Irish share issuance and pre‑emption waivers.
The proxy highlights 2025 performance, including approximately $1.48 billion in revenue and about $1.2 billion in proprietary product net sales, plus GAAP net income of roughly $242 million and Adjusted EBITDA of $394 million. It notes the completed acquisition of Avadel Pharmaceuticals, advances in the orexin 2 pipeline, and strong growth in VIVITROL, LYBALVI and ARISTADA. The filing also details CEO Richard Pops’ planned July 2026 retirement, Blair Jackson’s appointment as next CEO, extensive board refreshment and independence, pay‑for‑performance incentive design, and expanded ESG and shareholder‑engagement initiatives.
Alkermes plc filed Form 144 disclosing proposed sales of Common Stock linked to equity awards. The notice lists vesting of 1,164 restricted stock units and 870 performance share units (awarded in 2017 and 2015). The filing shows two proposed transactions dated 03/02/2026 and 03/03/2026 with amounts 59,575.86 and 60,531.84.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised employee stock options for 5,000 Ordinary Shares at an exercise price of $19.34 per share and acquired the related shares. On the same date, he sold 9,000 Ordinary Shares at a weighted average price of $35.5116 per share in an open-market transaction.
Both the option exercise and the share sale were effected under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025. After these transactions, Hopkinson directly held 85,389 Ordinary Shares. The options exercised were fully vested in accordance with their terms, and no remaining derivative positions are shown in this filing.
Alkermes plc: Craig Hopkinson reported multiple planned sales of Ordinary shares on Form 144, including transactions from 12/01/2025 through 03/02/2026. Recent reported sales include 9,000 shares on 02/02/2026 for $305,384.28 and 9,000 shares on 03/02/2026 for $267,485.14.
The filing also lists exercises and vesting events: a 5,000-share broker-assisted cashless exercise on 04/01/2026 and several performance share award vestings in 2025–2026. These entries are routine disclosures of secondary market sales and compensation-related issuances.
Alkermes plc is soliciting proxies for its 2026 Annual General Meeting of Shareholders to be held on May 20, 2026, subject to completion. The meeting will consider election of directors, advisory and ratification votes on executive compensation and auditor appointment, renewal of share-allotment and pre-emption authorities, and approval of the amended 2018 Stock Option and Incentive Plan.
Shareholders of record as of March 13, 2026 may vote. The filing highlights 2025 results including $1.48 billion total revenues, $1.2 billion proprietary product net sales, GAAP net income of $242 million, $394 million Adjusted EBITDA, and a year-over-year increase in cash and investments of approximately $495 million. The proxy statement discloses the CEO succession plan (CEO retirement effective July 31, 2026; successor effective August 1, 2026) and notes the completed acquisition of Avadel in February 2026.
Alkermes PLC Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Alkermes PLC common stock and 0% of the class. The filing notes an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, after which certain Vanguard subsidiaries report holdings separately.
The amendment is a disclosure of ownership status and reorganization-related reporting changes; it does not show any current beneficial ownership or voting/dispositive power by The Vanguard Group over Alkermes PLC common stock.
Reed Joshua reported acquisition or exercise transactions in this Form 4 filing.
Alkermes plc reported that its Senior Vice President and Chief Financial Officer, Joshua Reed, received new equity awards. On March 2, 2026, he was granted 66,430 employee stock options and 30,854 restricted stock units, each RSU representing one ordinary share.
The stock options and RSUs vest in four equal annual installments starting on March 2, 2027, meaning the awards will fully vest over four years if service-based conditions are met. These are non-cash compensation grants and do not represent open-market purchases or sales of Alkermes shares.
POPS RICHARD F reported acquisition or exercise transactions in this Form 4 filing.
Alkermes plc reported that Director and CEO Richard F. Pops received a grant of 88,843 restricted stock units on March 2, 2026. Each unit represents a contingent right to receive one ordinary share. The entire award is scheduled to vest on December 31, 2026 in connection with the company’s previously announced leadership transition.
Alkermes plc VP, Finance (Interim PAO) Samuel Joseph Parisi reported equity awards and a planned share sale. On 3/2/2026, he received an employee stock option for 15,033 shares at an exercise price of $0.00, vesting in four equal annual installments starting 3/2/2027.
He also received a restricted stock unit award for 14,176 units, each representing one ordinary share, vesting in four equal annual installments beginning 3/2/2027. On the same date, he sold 6,890 ordinary shares at $29.29 per share in an open-market transaction under a pre-established Rule 10b5-1 trading plan adopted on 11/7/2025.
Alkermes plc senior vice president and chief commercial officer Christian Todd Nichols reported both equity awards and a share sale. He received an employee stock option for 66,430 shares and a restricted stock unit award for 30,854 units, each at a grant price of $0.00 per share. Both the option and RSUs vest in four equal annual installments, starting on 3/2/2027. On the same date, he sold 6,000 ordinary shares at $30.00 per share in an open-market transaction effected under a pre-established Rule 10b5-1 trading plan adopted on 11/19/2025, and held 109,769 ordinary shares afterward.